logo
ODU professor explains why public is seeing a surge of food recalls

ODU professor explains why public is seeing a surge of food recalls

Yahoo2 days ago

NORFOLK, Va. (WAVY) — There were nearly and it doesn't stop there, as already in the first half of this year, the FDA has reported a staggering 45.
Whole cucumbers were recalled last week, over , and that has now expanded to 16 states, including Virginia. Within the last 24 hours a salmon product from Aldi was scrapped from shelves due to a life-threatening allergen in three states out west. And earlier Wednesday, that may be contaminated with foreign material, specifically wood.
These are prime examples of why there's a growing public concern. It's making consumers question what's safe to eat, and above all creates the greater risk for the development of foodborne illnesses. But are the recalls actually occurring more often?
Professor Rishi Drolia, with the Old Dominion University biological sciences department, said food recalls may appear increased over time because of advanced technology used by the CDC, USDA and FDA to track foodborne illnesses.
'I think stricter regulations are very important for food safety and for public health,' he said. 'In the United States, there is a zero-tolerance policy for listeria monocytogenes. In some of the European countries, there is some tolerance. That means a certain amount of listeria can be still present in ready to eat foods, but here, the regulations are very strict.'
Those tighter regulations help to track the outbreak faster through frequent checks of the processing plants, environmental sampling and sanitization. The other issue at hand is what the masses are consuming, along with lifestyle changes.
'People do not have time to cook,' Drolia said. 'The amount of ready-to-eat food products consumed has increased over the years. If you see, a majority of these outbreaks happen in a lot of fast food or raw food. And so in both the cases, what happens is that the people are consuming … food that is never cooked.'
Drolia also stresses the importance of knowing if you are immunocompetent or immunocompromised. Many people have compromised immune systems and are not aware.
'For the majority of the foodborne pathogens, and including listeria monocytogenes here, the risk population is young, elderly, pregnant and immunocompromised,' he said. 'And so, if you are in one of those susceptible groups, that is when you could avoid high risk foods and those high risk foods are ready to eat meat that are uncooked, unpasteurized milk, raw vegetables, raw fruits [and] cheese that is made up of unpasteurized milk.
He said to also thoroughly cook your food and practice safe food handling processes in your kitchen to avoid cross contamination. Those precautionary measures can help reduce illnesses, due to foodborne pathogens.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Food and fitness make or break success on weight loss meds, report finds

time34 minutes ago

Food and fitness make or break success on weight loss meds, report finds

Drugs like Wegovy and Zepbound -- GLP-1 medications typically used to treat obesity -- can lead to impressive weight loss. But a new joint advisory from four major medical groups warns that without proper nutrition and lifestyle support, people may face muscle loss, weight regain, and high long-term costs once they take themselves off GLP-1 medications. Experts from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association and The Obesity Society contributed to the report, which noted that only about half of users continue taking their GLP-1 medication after one year and only about 15% remain on treatment after two years. Many people stop taking GLP-1 medications due to side effects, cost or disappointing results -- and when they do, they often regain weight, making long-term success depend on consistent use and a healthy diet, the report stated. The report aims to guide both clinicians and patients on nutrition and lifestyle changes to improve long-term outcomes while taking a GLP-1. "We really wanted to bring in four major societies together that focus on nutrition, lifestyle, [and] obesity and come with a consensus statement on how nutrition should be thought about when prescribing these drugs," Dr. Dariush Mozaffarian, a cardiologist, director of the Food is Medicine Institute at Tufts University, and the report's lead author, told ABC News. Mozaffarian explained that for someone to achieve success on a GLP-1, they need to commit to comprehensive lifestyle changes. "The FDA says these drugs are approved for use as an adjunct to lifestyle therapy," he said. "In fact, they are prescribed the other way around with lifestyle therapy being the adjunct if being thought about at all. Doctors are not following either society guidelines or FDA guidelines if they are prescribing [GLP-1s] without lifestyle therapy." Before starting GLP-1 medications, the report recommended that patients work with their doctors to set goals that focus on overall health, not just weight loss. It's also important to check for any stomach or bone issues that could lead to side effects like nausea, vomiting, or muscle and bone loss, the report stated. "Registered dietitians can play really key roles in comprehensive obesity care by providing medical nutrition therapy to support GLP-1 therapy," said Emily A. Callahan, registered dietitian nutritionist and director of policy strategy for the Food is Medicine Institute. "The evidence space is growing that shows when registered dietitians deliver medical nutrition therapy, it has been associated with improvements in body weight, waist circumference, blood pressure and glycemic control." People should usually start GLP-1 medications at the lowest dose and slowly increase as needed, the report said. Patients should also be aware that nausea is common when taking these drugs and this may trigger cravings for sugary, high-calorie comfort foods that work against weight loss. To stay on track, the report recommended eating small, frequent meals and focusing on minimally processed, nutrient-rich foods. The report called for exercising special caution for anyone following an intermittent fasting diet or a low-carbohydrate "keto diet" that limits foods like breads, pastas and fruit to put the body into a state called ketosis, where it burns fat for fuel instead of carbs. These individuals might be especially vulnerable to gastrointestinal side effects, the report said. The report also advised people who may not be getting enough nutrients to consider taking supplements like vitamin D, calcium and multivitamins, while increasing protein intake by 50-100% from foods such as fish, eggs, nuts and seeds. This is especially important for those eating less while on GLP-1s, since lower food intake can make it harder to get all the nutrients the body needs. The report also underscored the importance of maintaining muscle mass and bone density while losing weight. Since weight loss can also lead to muscle loss -- especially in older adults -- the report advised doing a full body strength training routine at least three times a week and getting 150 minutes of moderate cardio each week. Focusing on nutrition, physical activity and other healthy lifestyle habits should give GLP-1 users a greater chance of achieving their goals, the report concluded. "GLP-1s have the best chance of helping people achieve and sustain lasting weight reduction when they are paired with strong nutrition guidance and lifestyle support," said Callahan.

Updated NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Recommend Use of FES PET Imaging for Lobular Breast Cancer
Updated NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Recommend Use of FES PET Imaging for Lobular Breast Cancer

Yahoo

timean hour ago

  • Yahoo

Updated NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Recommend Use of FES PET Imaging for Lobular Breast Cancer

NCCN Guidelines® recommend FES PET for systemic staging in certain patients with invasive lobular cancer (ILC), which could facilitate greater diagnostic accuracy, earlier interventions, better clinical decision-making and broader insurance coverage for breast cancer patients. GE HealthCare's Cerianna (fluoroestradiol F18) injection is the first and only U.S. Food and Drug Administration (FDA) approved imaging agent to help clinicians assess estrogen receptor positive (ER+) lesion status in recurrent or metastatic breast cancer. ARLINGTON HEIGHTS, Ill., May 30, 2025--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced that the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for clinicians now recommend considering fluoroestradiol (FES) positron emission tomography (PET) for systemic staging in patients with recurrent or metastatic lobular breast cancer. GE HealthCare's Cerianna™ (fluoroestradiol F18) injection, available in the United States, is the only FDA-approved imaging agent for the detection of estrogen receptor positive (ER+) breast cancer metastases, including lobular breast cancer. The updated NCCN Guidelines® expand the recommendation for the use of FES PET imaging in ER+ disease. In 2023, FES PET was included in the NCCN Guidelines for systemic staging of recurrent/stage IV ER+ breast cancer. According to the Breast Cancer Research Foundation, 95% of invasive lobular cancer (ILC) tumors are ER+.i ILC is the second most common type of breast cancer in the U.S., accounting for 10-15% of all breast cancers and an estimated 43,000 new cases each iii iv Lobular tumors typically do not form lumps which makes the cancer harder to detect with self-exams, mammography, ultrasound and magnetic resonance imaging (MRI). ILC can also recur more than a decadev after initial diagnosis and metastasize to unusual places such as the bones, brain, liver, lungs, gynecological organs, and Once recurrent or metastatic lobular breast cancer is suspected, the new guidelines recommend considering FES PET imaging of the whole body to assess whether ER+ lobular tumors are present. "Lobular cancers are often missed during routine screening, which can result in larger, more advanced tumors when they are finally detected and diagnosed," said Jit Saini, MD, Chief Medical Officer of the Pharmaceutical Diagnostics (PDx) division of GE HealthCare. "This NCCN Guidelines update is significant because it will give more oncologists the confidence to use Cerianna PET imaging for patients with lobular breast cancer. It may also facilitate broader insurance coverage so more patients with this common, but hard-to-detect cancer will have an opportunity to receive a comprehensive diagnosis that accelerates clinical decisions and early intervention." Cerianna is a molecular imaging agent indicated for use with PET imaging for the detection of ER+ lesions as an adjunct to biopsy in patients with known or suspected recurrent or metastatic breast cancer. Cerianna works by binding to functional ER lesions and then the whole body is imaged by PET scan to help doctors assess and treat lobular breast cancer appropriately. With its diffuse growth patterns, detection and biopsy of ILC can be more difficult. Cerianna provides an alternative method to assess ER status across the whole body. The recommendation that FES PET may be appropriate in lobular histology was established by an expert working group convened by the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and included breast care specialists from the SNMMI, Lobular Breast Cancer Alliance, American College of Nuclear Medicine and Korean Society of Nuclear Medicine. The SNMMI is a nonprofit organization that promotes the science, technology and practical application of nuclear medicine and molecular imaging. The National Comprehensive Cancer Network (NCCN®) is a not-for-profit alliance of 33 leading U.S. cancer centers devoted to patient care, research, and education. The NCCN Guidelines are the recognized standard for clinical direction and policy in cancer care and the most thorough and frequently updated clinical practice guidelines available in any area of medicine. GE HealthCare's Pharmaceutical Diagnostics segment is a global leader in imaging agents used to support around 130 million procedures per year globally, equivalent to four patient procedures every second. Its Molecular Imaging portfolio combines established proprietary products across cardiology, neurology and oncology, with an innovative pipeline, all aimed at enabling better informed diagnosis and monitoring for improved therapy decision making and clinical outcomes. Learn more about Cerianna here: About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient's journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits. GE HealthCare is proud to be among 2025 Fortune World's Most Admired Companies™. Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website for more information. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. IMPORTANT SAFETY INFORMATION FOR CERIANNA™ (FLUORESTRADIOL F18) INJECTION INDICATIONS AND USAGE: CERIANNA is indicated for use with positron emission tomography (PET) imaging for the detection of estrogen receptor (ER)-positive lesions as an adjunct to biopsy in patients with recurrent or metastatic breast cancer. Limitations of Use: Tissue biopsy should be used to confirm recurrence of breast cancer and to verify ER status by pathology. CERIANNA is not useful for imaging other receptors, such as human epidermal growth factor receptor 2 (HER2) and the progesterone receptor (PR). Important Safety Information CONTRAINDICATIONS None. WARNINGS AND PRECAUTIONS Risk of Misdiagnosis Inadequate Tumor Characterization and Other ER-Positive Pathology Breast cancer may be heterogeneous within patients and across time. CERIANNA images ER and is not useful for imaging other receptors such as HER2 and PR. The uptake of fluoroestradiol F 18 is not specific for breast cancer and may occur in a variety of ER-positive tumors that arise outside of the breast, including from the uterus and ovaries. Do not use CERIANNA in lieu of biopsy when biopsy is indicated in patients with recurrent or metastatic breast cancer. False Negative CERIANNA Scan A negative CERIANNA scan does not rule out ER-positive breast cancer. Pathology or clinical characteristics that suggest a patient may benefit from systemic hormone therapy should take precedence over a discordant negative CERIANNA scan. Radiation Risks Diagnostic radiopharmaceuticals, including CERIANNA, expose patients to radiation. Radiation exposure is associated with a dose-dependent increased risk of cancer. Ensure safe drug handling and patient preparation procedures (including adequate hydration and voiding) to protect patients and health care providers from unintentional radiation exposure. Pregnancy Status Assessment of pregnancy status is recommended in females of reproductive potential before administering CERIANNA. ADVERSE REACTIONS In Clinical Trials (n=1207) the most common adverse reactions seen occurred at a rate < 1% were injection-site pain and dysgeusia. USE IN SPECIFIC POPULATIONS Pregnancy Risk Summary All radiopharmaceuticals, including CERIANNA, have the potential to cause fetal harm depending on the fetal stage of development and the magnitude of radiation dose. Advise a pregnant woman of the potential risks of fetal exposure to radiation from administration of CERIANNA. There are no available data on CERIANNA use in pregnant women. No animal reproduction studies using fluoroestradiol F 18 have been conducted to evaluate its effect on female reproduction and embryo-fetal development. The estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. All pregnancies have a background risk of birth defects, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Lactation Risk Summary There are no data on the presence of fluoroestradiol F 18 in human milk, or its effects on the breastfed infant or milk production. Lactation studies have not been conducted in animals. Advise a lactating woman to avoid breastfeeding for 4 hours after CERIANNA administration in order to minimize radiation exposure to a breastfed infant. Pediatric Use The safety and effectiveness of CERIANNA in pediatric patients have not been established. Geriatric Use Clinical studies of fluoroestradiol F 18 injection did not reveal any difference in pharmacokinetics or biodistribution in patients aged 65 and over. DRUG INTERACTIONS Systemic Endocrine Therapies that Bind to ER Drugs that bind to the ER, including SERMs and SERDs, may compete with the binding of fluoroestradiol F18 and may reduce detection of ER-positive lesions with CERIANNA. Before administration of CERIANNA, discontinue drugs that bind to the ER, such as SERMs and SERDs, for at least 5 biological half-lives: (e.g. elacestrant for 11 days, tamoxifen for 8 weeks and fulvestrant for 28 weeks). Prior to Cerianna administration, please read the full Prescribing Information and additional Important Safety Information here. To report SUSPECTED ADVERSE REACTIONS, contact GE HealthCare at 800 654 0118 (option 2 then option 1) or by email at or FDA at 800 FDA 1088 or ______________________________ i Rubio M, et al. Invasive lobular carcinoma: symptoms, treatment, research. Breast Cancer Res. 2025 May 20. Available from: ii McCart Reed AE, et al. Invasive lobular carcinoma of the breast: the increasing importance of this special subtype. Breast Cancer Res. 2021 Jan 7;23(1):6. PMID: 33413533 iii Ciriello G, et al. Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. Cell. 2015 Oct 8;163(2):506-19. PMID: 26451490 iv 2021 Projected Incidence from ACS Surveillance Research (Source: SEER data) v Pestalozzi BC, et al. International Breast Cancer Study Group. Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials. J Clin Oncol. 2008 Jun 20;26(18):3006-14. PMID: 18458044 vi Franzoi MA, et al. Leptomeningeal carcinomatosis in patients with breast cancer. Crit Rev Oncol Hematol. 2019 Mar;135:85-94. PMID: 30819451 vii Blohmer M, et al. Patient treatment and outcome after breast cancer orbital and periorbital metastases: a comprehensive case series including analysis of lobular versus ductal tumor histology. Breast Cancer Res. 2020 Jun 26;22(1):70. PMID: 32586354 JB11825US 2025 View source version on Contacts GE HealthCare Media Contact: Emmy ElguizaouiCommunications Director – Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Here's Why Coffee Pros Love a Moka Pot — and How to Make the Perfect Cup
Here's Why Coffee Pros Love a Moka Pot — and How to Make the Perfect Cup

Yahoo

time2 hours ago

  • Yahoo

Here's Why Coffee Pros Love a Moka Pot — and How to Make the Perfect Cup

Making coffee doesn't have to be costly or complicated. The inexpensive stovetop moka pot should be a leading contender for an easy, top-quality brew. Invented in the 1930s by Alfonso Bialetti in Crusinallo, Italy, this modest coffee maker has become an archetypal symbol of efficient design around the world. Moka pot devotees have flooded social media with adoration and brewing tips. And top coffee professionals have joined in to share step-by-step tutorials. Renowned coffee expert James Hoffmann has dedicated several videos to the best practices and science behind the moka pot. He even sliced one in half to show its structure and inner workings. Related: Why the Best Coffee Is Made in a Moka Pot 'The moka pot extraction concept is based on speed, simplicity, and intensity of flavor,' says Simone Amenini, head of quality control and education for Ditta Artigianale and the Scuola del Caffè Firenze. 'It took the place of the cuccuma, the Neapolitan coffee pot — which isn't actually Neapolitan — widely used in Italian homes starting from the mid-1800s.' The moka pot could create a stronger-flavored brew, as it extracts the coffee grounds under pressure. 'This decidedly breaks with the trend in other European countries that continued to prefer a softer and smoother coffee on the palate, using infusion-based extractions like coffee pots, French press, syphon, and pour-over,' says Amenini. Moka pots were always present in the homes where Amenini grew up. 'For a long time, it represented the ideal of coffee at home,' he says. 'It represents the morning coffee that my parents prepare when I am at their house. It represents the after-meal coffee at my grandmother's house when we had the whole family gathered together.' A moka pot harnesses steam to push water up through ground coffee and into the top chamber where the completed brew sits. The boiler at the bottom of the pot is filled with water. As the water heats up, it begins to steam and expands the air to press the water up through a funnel and into the middle section, where the ground coffee sits in a basket. The liquid is then pushed through the grounds to the top chamber. The brewed coffee's journey is the opposite of the many drip coffee machines or pour-over methods which rely on gravity. These techniques allow water to drip down over grounds and into a pot below. Morgan Eckroth, drink developer and 2022 U.S. Barista Champion, prefers a moka pot to make coffee without the bells and whistles of a high-powered espresso machine. 'I've always found the tactile and methodical nature of the moka pot to be very grounding,' she says. 'I think, for many folks, moka pots hold a lot of nostalgia, and while I don't necessarily have those same memories, there's something about the brewing style that transports me back. It's a coffee maker that requires you to be present for every stage of the brew in a way that's pretty rare nowadays.' Eckroth loves to travel with a moka pot. Her go-to is the six-cup Bialetti Moka Express. 'It's a brewer that doesn't require the same level of gear that others typically do. A moka pot, grinder, heat source, and coffee are really all you need,' she says. 'A strong, hot cup of coffee from a moka pot while camping is my ideal scenario.' Many award-winning baristas gravitate to detailed brewing recipes with intensive focus on grind size, gram measurements, and water temperature. But the moka pot has been known to inspire a more intuitive process. 'While I'm a huge proponent of utilizing repeatable and trackable coffee recipes, I typically find myself reverting to simpler brewing with the moka pot,' says Eckroth. 'I fill the bottom chamber with preheated water up to the pressure valve and add enough medium-fine coffee to fill the basket. Following these two steps will usually result in a 1:10 ratio of coffee to water.' Eckroth recommends to put an AeroPress filter atop the grounds for an extra level of filtration. 'I start the brew on medium heat, and as soon as the first coffee rises into the upper chamber, I turn the heat down to low, and let it brew slowly,' she says. 'At the very first signs of sputtering, as the lower water chamber empties, I cover and remove the brewer. The coffee should then be served immediately.' Francesco Sanapo, co-founder of Ditta Artigianale and three-time Italian barista champion, feels a deep connection to the moka pot. 'The moka pot is a cultural symbol of Italy,' he says. 'When I was young, I would wake up for school to the smell of moka in my house. Moka plays an important role not only for me, but for all Italian people.' Sanapo uses a moka pot at breakfast every morning with his family. 'My best advice to is always use good, filtered water.' Los Angeles chef Royce Burke, the host of the Carpetbagger podcast, brews coffee in a moka pot daily. Burke's love of the moka pot is also sentimental. 'It's so simple, and the tradition of unscrewing it, tapping out the spent grinds, rinsing, filling the water chamber, grinding the beans by hand, pouring them in, screwing it back on, igniting the burner and listening for the gurgling sound of morning, it makes me so happy,' he says. Fill the bottom chamber with filtered water up to just below the safety valve (the pros often suggest to begin with boiling water for ideal extraction). Add medium-ground coffee to the filter basket. Level the grounds. Do not overfill or press down. Add an AeroPress filter over the coffee grounds for extra filtration (optional). Screw on the top of the moka pot and place the brewer on medium heat. Open the top of the pot to watch for the beginning of extraction. Keep an eye on the pot to see when the coffee begins to fill the top chamber. Take the pot off the heat before it begins to sputter with bubbles. Be careful in case the handle becomes hot on the stove. Close the top and wait a few minutes for the coffee to finish brewing. Most moka pots are not dishwasher safe, so clean them by hand. After you make coffee, rinse with hot water only, and dry thoroughly. When coffee oils build up, add vinegar or citric acid to water in the bottom chamber and brew normally to allow the mixture to enter the top chamber. Then rinse with fresh water. Read the original article on Food & Wine

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store